These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21654161)

  • 1. Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin.
    Shimizu H; Saitoh T; Ota F; Jimbo T; Tsukada Y; Murakami H; Nojima Y
    Acta Haematol; 2011; 126(2):114-8. PubMed ID: 21654161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pure red cell aplasia in patients treated with recombinant erythropoietin for anemia due to chronic renal disease].
    Miyazaki T; Obana T; Takasaki H; Tanaka M; Yamaji S; Fujimaki K; Fujita H; Kanamori H; Ishigatsubo Y
    Rinsho Ketsueki; 2007 May; 48(5):391-6. PubMed ID: 17571584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is antibody-mediated pure red cell aplasia (PRCA)?
    Casadevall N
    Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv3-8. PubMed ID: 15827056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk.
    Cournoyer D; Toffelmire EB; Wells GA; Barber DL; Barrett BJ; Delage R; Forrest DL; Gagnon RF; Harvey EA; Laneuville P; Patterson BJ; Poon MC; Posen GA; Messner HA;
    J Am Soc Nephrol; 2004 Oct; 15(10):2728-34. PubMed ID: 15466278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged course of pure red cell aplasia after erythropoietin therapy.
    Nigg L; Schanz U; Ambühl PM; Fehr J; Bachli EB
    Eur J Haematol; 2004 Nov; 73(5):376-9. PubMed ID: 15458518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.
    Macdougall IC
    Curr Med Res Opin; 2004 Jan; 20(1):83-6. PubMed ID: 14741076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks.
    Macdougall IC
    Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv9-15. PubMed ID: 15827058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic mechanisms of EPO-associated pure red cell aplasia.
    Schellekens H
    Best Pract Res Clin Haematol; 2005; 18(3):473-80. PubMed ID: 15792922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Early onset of anti- erythropoietin antibody-mediated pure red cell aplasia after commencement of subcutaneous administration of epoetin-β].
    Tanaka A; Tsukada J; Morimoto H; Katsuragi T; Nakanishi T; Watanabe S; Hirase N; Motomura S
    Rinsho Ketsueki; 2012 Jan; 53(1):110-2. PubMed ID: 22374534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: multiple options.
    Rossert J; Macdougall I; Casadevall N
    Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv23-26. PubMed ID: 15827054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse event issue management: what have we learnt from pure red cell aplasia (PRCA)?
    Macdougall IC
    Nephrol Dial Transplant; 2005 Sep; 20 Suppl 8():viii18-21. PubMed ID: 16079325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics of erythropoietin-associated pure red cell aplasia.
    Carson KR; Evens AM; Bennett CL; Luminari S
    Best Pract Res Clin Haematol; 2005; 18(3):467-72. PubMed ID: 15792921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pure red cell aplasia in erythropoietin therapy in patients with kidney failure].
    Opatrný K
    Cas Lek Cesk; 2003; 142(12):741-5. PubMed ID: 14746223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pure red cell aplasia secondary to treatment with erythropoietin.
    Locatelli F; Del Vecchio L
    J Nephrol; 2003; 16(4):461-6. PubMed ID: 14696747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies to recombinant human erythropoietin causing pure red cell aplasia.
    Prabhakar SS; Muhlfelder T
    Clin Nephrol; 1997 May; 47(5):331-5. PubMed ID: 9181281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures.
    Thorpe R; Swanson SJ
    Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv16-22. PubMed ID: 15827053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pure red cell aplasia as a complication of treatment with recombinant human erythropoietin].
    Grzegorzewska AE; Sucharzewska-Tomczak M
    Pol Merkur Lekarski; 2004 Oct; 17(100):407-9. PubMed ID: 15690716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resolution of epoetin-induced pure red cell aplasia 2 years later, successful re-challenge with continuous erythropoiesis receptor stimulator.
    Lim SK; Bee PC; Keng TC; Chong YB
    Clin Nephrol; 2013 Sep; 80(3):227-30. PubMed ID: 23298519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-mediated pure red cell aplasia related with epoetin-beta pegol (C.E.R.A.) as an erythropoietic agent: case report of a dialysis patient.
    Shingu Y; Nakata T; Sawai S; Tanaka H; Asai O; Tamagaki K; Nakatani K
    BMC Nephrol; 2020 Jul; 21(1):275. PubMed ID: 32664894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin and renal failure.
    Macdougall IC
    Curr Hematol Rep; 2003 Nov; 2(6):459-64. PubMed ID: 14561389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.